Prostate Cancer Screening: Who Should Get Tested and When

Prostate cancer screening is one of the most contested topics in preventive medicine — contested not because the disease is rare (it is the most common non-skin cancer in American men), but because the test used for screening, the PSA blood test, is sensitive but not specific, and because treatment of low-grade prostate cancer carries real risks of harm.

The debate is real and worth understanding. But so is the evidence that PSA-based screening, when applied thoughtfully to men at meaningful risk, reduces prostate cancer mortality. The question for any individual man is not whether screening is universally right or wrong — it is whether it makes sense for him, given his age, health, and risk profile.

What Is Prostate Cancer Screening?

Prostate cancer screening means testing men who have no symptoms of prostate cancer to detect cancer early. The primary tool is the PSA (prostate-specific antigen) blood test. PSA is a protein produced by the prostate gland; elevated levels can indicate prostate cancer, though they more commonly indicate benign prostatic hyperplasia (BPH), prostatitis, or other non-cancerous conditions.

Digital rectal examination (DRE) was historically part of every prostate cancer screening evaluation and remains useful: a hard nodule or asymmetry detected on DRE can indicate cancer even when PSA is in the normal range, and DRE abnormalities lower the threshold for referral to urology regardless of PSA level.

Screening does not diagnose cancer — it identifies men who may warrant further evaluation. An elevated PSA leads to additional testing: adjunct biomarkers, MRI, and potentially biopsy. A biopsy that finds cancer leads to staging and treatment decisions. This cascade of evaluation is what screening sets in motion.

Who Should Be Screened?

The answer depends on age, race, and family history. Major guidelines converge on a risk-stratified approach:

Average-risk men: Begin the shared decision-making conversation about PSA screening at age 50. The conversation — not necessarily the first PSA test — starts at 50, and the decision to screen is individualized based on the patient’s values, health status, and life expectancy.

African American men: Begin the conversation at age 40. African American men face approximately 70 percent higher incidence and roughly twice the mortality compared to white men. Earlier discussion reflects this substantially higher risk and the potentially greater benefit of early detection. This recommendation is made by the AUA, NCCN, and the American Cancer Society.

Men with a first-degree relative (father or brother) diagnosed with prostate cancer before age 65: Begin discussion at age 40. The risk of prostate cancer is approximately double that of the general population in men with one affected first-degree relative, and higher still with multiple relatives affected.

BRCA2 carriers: Begin discussion at age 40, with many guidelines recommending annual PSA testing once started. BRCA2 mutation carriers have a 5–8 times higher risk of prostate cancer and are more likely to develop aggressive disease. Understanding your overall prostate cancer risk profile — including genetic factors — directly informs the right time to start.

Men over 70 or with significant comorbidities and limited life expectancy: PSA screening is generally not recommended. Prostate cancer detected at age 75 in a man with significant other health problems is unlikely to affect his lifespan, and the harms of screening — including anxiety, unnecessary biopsy, and overtreatment — are less justified when competing causes of death are more probable.

What the Major Guidelines Say

The guidelines from major medical organizations have converged significantly in recent years, though they frame the recommendation differently:

USPSTF (U.S. Preventive Services Task Force), 2018: The USPSTF issued a Grade B recommendation — meaning a recommendation to offer the service — for PSA-based screening in men aged 55 to 69, with the caveat that the decision be individualized through shared decision-making. Grade B means the USPSTF believes the benefit outweighs the harm but that individual values matter in the decision. For men 70 and older, the USPSTF recommends against screening (Grade D).

AUA/SUO Guideline, 2023: The American Urological Association recommends against screening before age 40 for average-risk men and against routine screening from 40 to 54 (noting it is appropriate for higher-risk men in this age group). For men 55 to 69, shared decision-making is recommended, with PSA offered every one to two years rather than annually. Screening is not recommended for men over 70 with a life expectancy under 10–15 years.

NCCN, 2024: The most detailed age-stratified approach: baseline PSA at 45 for average-risk men (with earlier for high-risk); subsequent intervals based on PSA level (every 1–2 years if PSA 1–3 ng/mL; every 1–4 years if PSA below 1 ng/mL).

American Cancer Society, 2023: Recommends discussing screening at 50 for average-risk, 45 for African American men and those with one first-degree relative with prostate cancer diagnosed before 65, and 40 for men with more than one first-degree relative with early-onset prostate cancer.

Why Guidelines Disagree on Screening

If the major trials show that PSA screening reduces prostate cancer mortality, why did the USPSTF previously recommend against it (2012 Grade D recommendation, since upgraded to B) and why does any debate persist?

The core tension is the balance between benefit and harm. The benefit — reduced prostate cancer mortality — is real but modest in absolute terms: the ERSPC trial showed approximately 1.28 lives saved per 1,000 men screened over 13 years. The harms are also real:

• Overdiagnosis: Some prostate cancers detected through screening would never have caused symptoms or death in the man’s lifetime. Treating these cancers exposes men to the side effects of treatment (incontinence, erectile dysfunction) without benefit.
• False positives: Many men with elevated PSA who undergo biopsy do not have cancer. Biopsy itself carries risks of pain, bleeding, and infection.
• Anxiety: Elevated PSA results and the diagnostic workup that follows cause significant psychological distress even when cancer is ultimately not found or is low-grade.

The 2012 USPSTF Grade D recommendation reflected a judgment that these harms outweighed the benefits for average-risk men — a judgment heavily influenced by the PLCO trial, which showed no mortality benefit, versus the ERSPC trial, which did. The difference was largely explained by higher contamination in the PLCO control arm (many “unscreened” men had already received PSA tests before enrollment) and differences in follow-up duration. Subsequent longer follow-up of the ERSPC and Göteborg trials has strengthened the case for screening benefit, leading to the 2018 upgrade to Grade B.

Who Benefits Most From Screening

The men who benefit most from prostate cancer screening are those whose cancer — if detected early — would have progressed to cause harm, and who have sufficient life expectancy to benefit from early treatment.

This means men who are younger (under 70), in good health, at elevated risk (Black men, men with family history, BRCA2 carriers), and who would be candidates for curative treatment if cancer were found tend to benefit more from screening than older men with significant comorbidities.

Men who have already made a clear informed choice — after understanding the potential for overdiagnosis and overtreatment — and who want to know their PSA status are also appropriate candidates for screening. Autonomy matters in this decision.

What Happens at a PSA Screening Visit

For many men, the process of PSA screening is straightforward and involves no discomfort beyond a blood draw:

1. Preparation: Avoid ejaculation for 48 hours before the blood draw. Avoid vigorous cycling or perineal pressure for 24–48 hours. Do not schedule the PSA draw immediately after a DRE or within 4–6 weeks of any prostate procedure. Disclose any medications including finasteride or dutasteride, which lower PSA by approximately 50%.
2. The blood draw: PSA is measured from a standard venous blood sample. Results typically return within 24–48 hours.
3. DRE (optional but recommended): The physician may perform a digital rectal exam to assess prostate size and feel for nodules. A DRE abnormality can trigger referral even with a normal PSA.
4. Interpreting results: Your physician will interpret the PSA in context — your age, PSA trend over time, prostate size, and risk factors all factor in. An isolated slightly elevated result often leads to repeat testing under controlled conditions rather than immediate biopsy.
5. If PSA is elevated: Further evaluation follows. This may include adjunct blood tests (% free PSA, PHI, 4Kscore), MRI of the prostate, and potentially biopsy if MRI shows suspicious findings. For a detailed guide to this pathway, see our article on what to do when PSA is high.

How Often Should Screening Happen?

Screening interval should be tailored to PSA level rather than a fixed annual schedule:

• PSA below 1 ng/mL: Very low risk; repeat testing every 2–4 years is appropriate for most men in this range
• PSA 1 to 3 ng/mL: Repeat every 1–2 years
• PSA above 3 ng/mL but below the threshold for evaluation: More frequent monitoring and consideration of adjunct testing
• PSA above 4 ng/mL (or above age-adjusted normal): Evaluation pathway begins — repeat testing, adjunct biomarkers, MRI consideration

Men who have a baseline PSA below 1 ng/mL at age 60 have a very low probability of ever developing clinically significant prostate cancer and may need less frequent screening thereafter. Men with a PSA above 2 ng/mL at 60 have higher long-term risk and benefit from more frequent monitoring.

Frequently Asked Questions

Do I need a PSA test every year?

Not necessarily. Annual testing is appropriate for men at elevated risk (Black men, those with family history of prostate cancer, BRCA2 carriers) and for men whose PSA has been in the 1–3 ng/mL range. Men with very low PSA (below 1 ng/mL) can safely extend to every two to four years. The NCCN guidelines provide interval recommendations based on PSA level, and most urologists individualize the interval based on a man’s specific PSA trend and risk profile.

Will my insurance cover a PSA test?

In the United States, most private insurance plans and Medicare cover PSA screening for men over 50 as a preventive service. The 2018 USPSTF Grade B recommendation for men 55–69 means that, under the Affordable Care Act, this screening should be covered without cost-sharing for men in that age group by most insurers. Coverage for men under 55 or over 70 depends on the plan. Confirm with your insurer before scheduling if cost is a concern.

Can PSA screening detect prostate cancer 100% of the time?

No. PSA screening misses approximately 20–25% of clinically significant prostate cancers — these are cancers that occur in men with PSA below the threshold used for further evaluation. High-grade tumors, in particular, can produce relatively little PSA. This false-negative rate is why DRE remains a complementary tool, and why any concerning symptom — like a hard nodule felt on rectal exam — warrants evaluation regardless of PSA level. For more detail on how the PSA test works and what affects the result, see our dedicated article.

Sources

• USPSTF. Prostate Cancer Screening. JAMA 2018.
• AUA/SUO Early Detection of Prostate Cancer Guideline 2023.
• National Comprehensive Cancer Network. Prostate Cancer Early Detection v1.2024.
• Schroder FH et al. ERSPC trial. NEJM 2009.
• Hugosson J et al. Goteborg-2 randomised controlled prostate cancer screening trial. Lancet Oncol 2022.

The Göteborg and ERSPC Trials — Why the Long-Term Data Changed the Debate

The Göteborg randomized controlled trial, launched in Sweden in 1994 and recently published with 22-year follow-up in the Lancet Oncology (2022), provides some of the most compelling evidence for PSA screening benefit. Men randomized to biennial PSA screening experienced a 46 percent relative reduction in prostate cancer mortality compared to unscreened controls — a substantially larger benefit than seen in earlier publications, reflecting the longer observation period required for prostate cancer screening benefit to manifest.

The ERSPC (European Randomized Study of Screening for Prostate Cancer), a larger multi-country trial, showed a 25–32 percent relative reduction in prostate cancer mortality at 16 years with PSA-based screening. Both trials now demonstrate that the mortality benefit of PSA screening — long contested by the USPSTF’s 2012 analysis — is real and clinically meaningful when sufficient follow-up time is allowed.

The PLCO trial, conducted in the United States, initially showed no benefit from PSA screening. Subsequent analysis revealed extensive “contamination” — more than 40 percent of men in the control group received PSA screening outside the study. This contamination effectively narrowed the difference between the screened and unscreened groups, obscuring any true screening benefit. Reanalysis accounting for contamination found a mortality reduction consistent with the European trials.

Digital Rectal Examination in Screening

The DRE — digital rectal exam — was historically a central part of prostate cancer screening. Its role has diminished as PSA testing became dominant, but it retains clinical value that should not be dismissed.

A suspicious DRE finding (a hard nodule, asymmetry, or loss of the central sulcus) warrants urological referral regardless of PSA level — because some prostate cancers are palpable on DRE before they significantly elevate PSA. The AUA guideline retains DRE as a complementary component of baseline prostate evaluation, and most urologists include it in their initial evaluation of a man referred for elevated PSA or prostate cancer concern.

Men who are reluctant about DRE should know that the exam takes approximately 30 seconds, produces brief discomfort rather than significant pain, and can detect cancers that PSA alone would miss. For a man over 50 having the screening conversation, combining PSA with DRE provides a more complete clinical picture.

Prostate Cancer Screening After a Family History Diagnosis

When a man’s father, brother, or son is newly diagnosed with prostate cancer, it often triggers concern about personal risk. This is a reasonable response — first-degree family history approximately doubles the lifetime risk.

What should happen next depends on current age and screening status:

• If you are already being screened with PSA: notify your physician of the family history. It may warrant moving from biennial to annual testing and lowering the threshold for further evaluation.
• If you have never had a baseline PSA and are between 40 and 54: schedule a baseline PSA and DRE. A man with one first-degree relative diagnosed with prostate cancer is no longer “average risk” for purposes of screening timing.
• If you are over 55 and have been having regular PSA tests with consistently low results: continue your current schedule, but inform your physician of the family history so it can inform interpretation of future results.
• If the family history includes BRCA2 or other hereditary cancer mutations: ask for genetic counseling referral. BRCA2 changes both screening timing and potentially surveillance intensity once started.

The newly diagnosed family member’s Grade Group matters too. A brother with Grade Group 1 prostate cancer managed on active surveillance has a different implication than a brother with Grade Group 4 cancer requiring treatment. Understanding the family member’s actual diagnosis — not just “prostate cancer” — helps your physician assess the hereditary risk more precisely. If the recently diagnosed family member was found to carry a BRCA2 mutation, all male first-degree relatives should be offered genetic testing. Understanding the landscape of prostate cancer risk factors, including genetic and hereditary contributions, will help frame this conversation with your physician.

Psychological Aspects of Prostate Cancer Screening

The decision to undergo PSA screening is not purely clinical — it has meaningful psychological dimensions that should factor into the shared decision-making discussion.

Men who undergo screening and receive an elevated result experience significant anxiety in the period between receiving the result and completing the evaluation pathway — including any biopsy and pathology report. This “diagnostic uncertainty period” can last weeks to months and causes measurable psychological distress even when cancer is ultimately not found. Men who score highly on anxiety or health-related worry may experience this distress more acutely.

On the other hand, men who choose not to screen and subsequently develop symptomatic prostate cancer often experience regret about that decision — particularly if the cancer is found at an advanced stage.

A genuine shared decision-making conversation about prostate cancer screening should acknowledge both: the potential for anxiety and harms from evaluation if PSA is elevated, and the potential regret from not having detected a curable cancer early. A man’s tolerance for uncertainty, his feelings about the potential treatments involved, and his values around early detection versus avoiding unnecessary procedures are all legitimate inputs into the decision. If a PSA does come back elevated, understanding what happens next — and that most elevated PSA results do not represent cancer — can significantly reduce the distress associated with that result.

Balancing Benefit and Harm — Making the Decision That Is Right for You

Prostate cancer screening is one of the few medical decisions in men’s health where guidelines explicitly state that personal values and preferences should drive the individual choice. This is not a hedge — it reflects the genuine uncertainty about whether the benefit of early detection outweighs the harms of overdiagnosis and overtreatment for any particular person.

Men who tend to value peace of mind through knowing their status, who want to maximize the chance of catching cancer early, and who feel they could manage the anxiety of a workup if their PSA is elevated are generally well-suited to PSA screening. Men who feel that the process of evaluation would itself cause significant distress, who are not candidates for treatment due to age or health status, or who have clearly stated they would not want aggressive treatment for low-grade cancer even if found, may reasonably choose not to screen.

Neither choice is wrong when made with full information. What is wrong is not having the conversation at all — either screening without discussion of the harms, or never raising the topic with a physician. For men 50 and over (or 40 and over for African American men and those with family history), bringing up prostate cancer screening with your doctor is appropriate, even if you ultimately decide together that it is not right for you right now. To understand what an elevated screening result would lead to next, reviewing what happens when PSA is high before your appointment can make that conversation significantly more productive.